---
id: 028
title: Cefepime (4th Generation) - Spectrum and Uses
category: antimicrobials
subcategory: cephalosporins
tags: [cefepime, 4th-generation, Pseudomonas, AmpC, febrile-neutropenia]
difficulty: medium
---

## Question

What makes **cefepime (4th generation)** unique among cephalosporins, and what are its key clinical uses?

## Answer

### **Unique Features of Cefepime:**

1. **AmpC β-lactamase stability:**
   - Active vs AmpC-producing organisms (*Enterobacter*, *Citrobacter*, *Serratia*)
   - Less likely to induce AmpC expression vs 3rd-gen cephalosporins

2. **Broad dual spectrum:**
   - **Gram-positive:** Similar to 3rd-gen (MSSA, Streptococci) - NOT MRSA
   - **Gram-negative:** Best among cephalosporins (Enterobacterales + *Pseudomonas*)

3. **CNS penetration:**
   - Can be used for meningitis (though ceftriaxone preferred for *S. pneumoniae*)
   - Risk of **neurotoxicity** (encephalopathy, seizures) with high doses or renal impairment

### **Clinical Uses:**

| Indication | Rationale |
|------------|-----------|
| **Febrile neutropenia** | Monotherapy (covers *Pseudomonas* + Gram-pos) |
| **Hospital-acquired pneumonia** | Broad spectrum (± *Pseudomonas*) |
| **Complicated UTI** | *Pseudomonas* coverage |
| **Intra-abdominal infections** | + metronidazole for anaerobes |
| **Meningitis** | Gram-negative meningitis (especially *Pseudomonas*) |

### **Dosing:**
- **Standard:** 1-2g IV q8-12h
- **Severe *Pseudomonas*:** 2g IV q8h (extended infusion 3-4 hours preferred)
- **Renal adjustment:** Required (CrCl <60 mL/min)

## Key Points

### **Cefepime vs Ceftazidime:**
- **Cefepime:** Better Gram-positive + similar *Pseudomonas* activity
- **Ceftazidime:** Better *Pseudomonas*, weaker Gram-positive (no MSSA)

### **Cefepime vs Piperacillin-Tazobactam:**
- Both cover *Pseudomonas* and Enterobacterales
- **Cefepime:** NO anaerobe coverage, better vs AmpC producers
- **Pip-tazo:** Covers anaerobes, broader empiric choice

### **Neurotoxicity Risk:**
- **High-dose + renal impairment** → encephalopathy, myoclonus, seizures
- Monitor for confusion/altered mental status
- Reduce dose if CrCl <60 mL/min

## Sources

- [PMC9345683: Clinical PK/PD of Cefepime]
- [StatPearls: Cephalosporins]
- [IBCC: Cefepime vs Pip-Tazo Comparison]

## Media

N/A
